Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CorMedix, Inc. (CRMD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.23-7.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.06 → 0.03 EPS · FY ending Dec 31, 2027 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 4 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CRMD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Full-year 2026 adjusted EBITDA of $115M to $135M | Profit is expected near $125 million adjusted EBITDA in 2026. | Intact | Adjusted EBITDA falls below $115 million in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a commercial growth story with meaningful execution risk, rather than a steady compounder. The long-term thesis is intact, but quarterly sales have been uneven and confidence in the evidence is medium.
The valuation signal is cheap versus peers, while the model also shows a modest premium versus peers, so the comparison is not fully consistent. Expectations are tagged as justified, with low fragility, but valuation rose recently and near-term results still carry a notable risk of a miss.
Near term, revenue may remain uneven: company revenue declined from Q1 to Q2, even as adjusted EBITDA guidance rose and full-year revenue guidance was maintained. The multi-year case depends on turning expanded dialysis-provider contracts into sustained DefenCath sales and advancing REZZAYO’s expanded indication after FDA review; recent litigation adds risk.
A guidance cut at the next call would be a meaningful negative, while continued delivery against 2026 guidance would support the thesis. Weakening job growth could weigh on the healthcare sector, while strong results and higher guidance from sector bellwethers could provide a tailwind.
Over the next 1 to 3 years, CRMD’s thesis rests on converting broader access into durable sales while meeting guidance and progressing REZZAYO through regulatory review. Recent performance supports an intact thesis, but uneven quarterly revenue, execution risk, and litigation leave important uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in CorMedix, Inc.'s published investment case. The stated target is >= $100 million. |
| Intact |
| DefenCath sales fall below $100 million in 2027 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Consistent progress on revenue and profit targets | A supporting condition in CorMedix, Inc.'s published investment case. The stated target is Maintain or improve progress score >= 66%. | Broken | Progress score falls below 66% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Full-year 2026 revenue of $325M to $345M | A primary condition in CorMedix, Inc.'s published investment case. The stated target is >= $325 million. | Intact | Full-year 2026 revenue falls below $325 million | Revenue: $101.931M FY2026-Q2; GAAP. Published target: >= $325 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026101,931,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.09 → $0.03 · observed estimates
$0.29B → $0.28B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-07-25 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-07-26 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-07-27 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-07-28 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-07-29 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-07-30 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-07-31 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-08-01 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-02 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-08-03 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-04 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-05 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-06 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-07 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-08 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-08-09 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-10 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-11 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-08-12 | $0.09 | $285,221,800 | 5 / 5 |
| 2026-08-13 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-14 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-15 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-16 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-17 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-18 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-19 | $0.09 | $285,220,000 | 3 / 3 |
| 2026-08-20 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-21 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-22 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-23 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-24 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-25 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-26 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-27 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-28 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-29 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-30 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-08-31 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-01 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-02 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-03 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-04 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-05 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-06 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-07 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-08 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-09 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-10 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-11 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-12 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-13 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-14 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-15 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-16 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-17 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-18 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-19 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-20 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-21 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-22 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-23 | $0.06 | $286,451,600 | 3 / 3 |
| 2026-09-24 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-09-25 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-09-26 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-09-27 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-09-28 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-09-29 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-09-30 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-01 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-02 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-03 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-04 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-05 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-06 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-07 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-08 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-09 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-10 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-11 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-12 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-13 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-14 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-15 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-16 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-17 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-18 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-19 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-20 | $0.06 | $289,266,333 | 4 / 4 |
| 2026-10-21 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-22 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-23 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-24 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-25 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-26 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-27 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-28 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-29 | $0.06 | $289,272,067 | 4 / 4 |
| 2026-10-30 | $0.07 | $287,350,400 | 4 / 4 |
| 2026-10-31 | $0.07 | $287,350,400 | 4 / 4 |
| 2026-11-01 | $0.07 | $287,350,400 | 4 / 4 |
| 2026-11-02 | $0.07 | $287,350,400 | 4 / 4 |
| 2026-11-03 | $0.07 | $287,350,400 | 4 / 4 |
| 2026-11-04 | $0.03 | $281,478,000 | 4 / 4 |
| 2026-11-05 | $0.03 | $281,478,000 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.